-+ 0.00%
-+ 0.00%
-+ 0.00%

ProMIS Neurosciences says PMN310 cuts amyloid-beta oligomers in human CSF in Phase 1a data

PUBT·07/14/2026 06:30:33
Listen to the news
ProMIS Neurosciences says PMN310 cuts amyloid-beta oligomers in human CSF in Phase 1a data
  • ProMIS Neurosciences reported first human evidence that PMN310 reduced amyloid-beta oligomers in CSF in a Phase 1a healthy-volunteer study.
  • Data showed a dose-dependent drop in detectable oligomer particles at three days and 29 days following a single dose.
  • Company expects blinded six-month interim data from its PRECISE-AD Phase 1b trial in the coming weeks.
  • Top-line unblinded Phase 1b results are expected in early Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607140230PRIMZONEFULLFEED9761509) on July 14, 2026, and is solely responsible for the information contained therein.